Hope S. Rugo Professor of Medicine; Director, Breast Oncology and Clinical Trials Education; UCSF Comprehensive Cancer Center 5Live #ASCO20
6:58
"Key Insights on Alpelisib + fulvestrant in PIK3CA-mutated HR+/HER2– advanced BC previously treated with CDK 4/6 inhibitor + aromatase inhibitor (AI): BYLieve study results "
Breast Cancer
Hope S. Rugo Professor of Medicine; Director, Breast Oncology and Clinical Trials Education; UCSF Comprehensive Cancer Center 5Live #ASCO20
"Key Insights on Alpelisib + fulvestrant in PIK3CA-mutated HR+/HER2– advanced BC previously treated with CDK 4/6 inhibitor + aromatase inhibitor (AI): BYLieve study results "
Breast Cancer Similar Videos
Similar Videos
-
Building Health Equity and Multidirectional Trust in Cancer Care_Breast & Colorectal Cancer_Lisa Newman, MD, MPH, FACS, FASCO, FSSO_Laura Musselwhite, MD, MPH
50:13
-
Harnessing the Power of Antibody-Drug Conjugates for the Treatment of Hematologic and Solid Cancer: Leveraging Antibody-Drug Conjugates in Breast Cancer Care_Hope Rugo, MD, FASCO
53:15
-
Keerthi Gogineni, MD, MSHP; Emory University Winship Cancer Institute; #DDHO2022
11:51
